<DOC>
	<DOC>NCT01197482</DOC>
	<brief_summary>Investigational device: AKITA 2 device versus conventional metered-dose inhaler (MDI) Objectives: To explore if inhalative fluticasone application by means of the AKITA technology would result in a better symptom control in patients with severe persistent asthma as compared to inhalative application of fluticasone by a conventional MDI. Study design: open label, cross-over (one AKITA, one MDI arm) Patients: 20 Patients with severe persistent asthma</brief_summary>
	<brief_title>Inhaled Steroids and Control of Severe Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Severe persistent asthma bronchiale with diagnosis according to the criteria of the Global Initiative for Asthma (GINA) executive summary Treatment with at least inhaled corticosteroids (ICS) and long acting b agonists (LABA) Evidence of inflammatory triggered form of asthma with at least one of the following: sensitization to typical aerogenous allergens increased Serum IgE levels Eosinophilia in peripheral blood Proven Eosinophilia in sputum differential (&gt; 3%) in the previous 2 years at least 2 exacerbations of asthma within the previous 24 months leading to unscheduled presentation at a health care provider and/or systemic corticosteroid Signed informed consent Requirements of the local ethics committee are met Acute exacerbation of asthma within the last 6 weeks Rtot &gt; 350% predicted capillary pO2 &lt; 60mmHG, pCo2 &gt; 50mmHG near fatal asthma or anaphylaxis in history Age â‰¤ 18 and &gt; 80 years Active smoking or &gt; 15 packyears former smoking Oral steroid treatment with a prednisolonequivalent dose exceeding 10 mg per day Pregnancy, nursing females Female without use of effective contraceptive method Treatment with investigational drugs over the past 30 days or during the course of the trial Severe and uncontrolled gastroesophageal reflux disease Ongoing psychiatric disorder Treatment with systemic corticosteroids for any reason other than asthma Other active lung diseases Medical history of other uncontrolled diseases 3 months prior randomization (e.g. infections, coronary heart diseases and metabolic diseases) Any history of malignancy requiring ongoing treatment and/or limiting lifeexpectancy Clinically significant abnormalities in electrocardiogram (ECG) or laboratory exams Asthma related to nonsteroidal antiinflammatory drug (NSAID) Insulin dependent diabetes mellitus Cataract</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>asthma</keyword>
	<keyword>inhalation</keyword>
</DOC>